Preferences for pharmacogenomic testing in polypharmacy patients: a discrete choice experiment Supplementary Appendix

Aim: To elicit preferences for pharmacogenomic (PGx) testing in polypharmacy patients. Materials & methods: A face-to-face discrete choice experiment survey was designed and administered to adult polypharmacy patients recruited at a local retail pharmacy in Albuquerque (NM, USA). Results: A total of 128 eligible polypharmacy patients completed the discrete choice experiment survey and significantly preferred a PGx test with lower cost, better confidentiality and higher certainty of identifying best medication/dose and side effects and one that can be used to advocate for their treatment needs (all p < 0.01). Conclusion: This is the first study eliciting preferences for PGx testing among polypharmacy patients. The study found most polypharmacy patients were willing to take a PGx test and their preferences were mostly influenced by test cost.研究目的：明确多重用药患者对药物基因组学（pharmacogenomic, PGx）检测的偏好。 材料与方法：设计并开展面对面离散选择实验（discrete choice experiment）问卷，对美国新墨西哥州阿尔伯克基市某本地零售药房招募的成年多重用药患者进行调研。 结果：共计128名符合纳入标准的多重用药患者完成了本次离散选择实验问卷，且显著更青睐具备以下特征的药物基因组学检测：检测成本更低、保密性更佳、可更精准地确定最佳药物/给药剂量及不良反应，且可用于为其治疗诉求提供支撑（所有指标的p值均<0.01）。 结论：本研究为首个针对多重用药患者群体开展药物基因组学检测偏好调研的研究。结果显示，多数多重用药患者愿意接受药物基因组学检测，且其偏好主要受检测成本影响。